Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Global markets in deep red
Fri, 27 Nov 12:30 pm

Taking cues from the weakness across global markets, the benchmark indices on Indian bourses nose-dived deeper into the negative territory during the previous two hours of trade. The market wide carnage left all sectors writhing in red. The stocks from realty, metal and banking sectors have been the maximum losers so far.

The BSE-Sensex is trading deep in red, down by around 541 points while NSE-Nifty is down 161 points. The BSE-Midcap and BSE-Smallcap are also trading lower, down by around 3.7% each. The rupee is trading at 46.86 to the dollar.

According to a leading business daily, Indian IT majors are vying for domestic opportunities for IT services in the Indian power distribution sector. Under Restructured - Accelerated Power Development and Reform Programme (R-APDRP), Indian government is aiming to reform the ailing power distribution sector. It aims at reducing the aggregate technical and commercial losses in power distribution sector to 15% from the existing 30%. For this purpose it has planned Rs 100 bn IT automation project spanning over next 3 years.

Power Finance Corporation (PFC), the nodal agency responsible for R-APDRP is seeking bids from IT companies like TCS, HP, Mahindra Satyam, Patni Computers for building the IT backbone to detect points of power losses and aid corrective actions. It may be noted that total funds of Rs 516 bn are allocated to R-APDRP during eleventh plan. Indian IT majors have a lot to gain from the same.

Daiichii-controlled Ranbaxy will be launching the generic version of GlaxoSmithKline's (GSK) blockbuster anti-herpes drug in the US. Ranbaxy holds the first-to-file status for the drug which gives it six-month exclusivity for marketing the same in the US. During this period no other company except GSK and Ranbaxy will be allowed to market this drug.This appears to be positive news for Ranbaxy as it might generate as much as US $ 200 m in sales the world's largest drug market. It may be noted that Ranbaxy saw a sharp decline in its US revenues in FY09 on account of regulatory issues it faced from US Food and Drug Administration (USFDA). The USFDA had banned all the products from two of Ranbaxy's Indian manufacturing plant. However, Ranbaxy managed to make the anti-herpes drug from its facilities in the US itself.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Global markets in deep red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.